Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JANX013 · 1 trial · 4 indications
Cytokine release syndrome (CRS) assessed according to ASTCT criteria.
| Arm | Type | Description |
|---|---|---|
| Dose Escalation | EXPERIMENTAL | Participants receive JANX013 in combination with JANX007 administered at increasing dose levels per cohort |
| Dose Expansion | EXPERIMENTAL | Participants receive JANX013 in combination with JANX007. Participants will be dosed at levels previously declared tolerable. |
| Name | Type | Description |
|---|---|---|
| JANX013 | DRUG | JANX013 will be administered via IV dosing. |
| JANX007 | DRUG | JANX007 will be administered via IV dosing. |
Key Inclusion Criteria: * Male participants ≥ 18 years of age at the time of signing informed consent * Histologically or cytologically confirmed adenocarcinoma of the prostate For Dose Escalation: \- Have received at least 1 novel ARPI (e.g., abiraterone acetate, enzalutamide, apalutamide, or da...
Top 20 of 52 competitors